Molecule
Toripalimab is a programmed death receptor-1 blocking antibody indicated in combination with cisplatin and gemcitabine, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Toripalimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy
Source: US FDA prescribing information
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Toripalimab-tpzi is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Source: US FDA prescribing information
In combination with cisplatin and gemcitabine: 240 mg intravenously every three weeks. As a single agent: 3 mg/kg intravenously every two weeks. First Infusion: Infuse over 60 minutes. Subsequent Infusions: If no infusion-related reactions occurred during the first infusion, subsequent infusions may be administered over 30 minutes.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Immune-Mediated Adverse Reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection. Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. Withhold or permanently discontinue based on severity and type of reaction. Infusion-related reactions: Interrupt, slow the rate of infusion, or permanently discontinue LOQTORZI based on the severity of reaction.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Severe and fatal immune-mediated adverse reactions Infusion-related reactions Complications of Allogeneic HSCT LOQTORZI in Combination with Cisplatin and Gemcitabine The most common adverse reactions (≥ 20%) are nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, dizziness, and malaise. LOQTORZI as a Single Agent The most common adverse reactions (≥ 20%) are fatigue, hypothyroidism and musculoskeletal pain.
Source: US FDA prescribing information
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Toripalimab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Loqtorzi 240 mg/6 mL injectionIntravenous Cold chain | Coherus Oncology | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Toripalimab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Toripalimab, including Loqtorzi.
Yes. The US FDA first approved Toripalimab on 27 October 2023, according to Drugs@FDA.
Yes. Toripalimab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Toripalimab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Toripalimab is classified under ATC code L01FF13 (Toripalimab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.